Urinary proteomic biomarkers in oncology: ready for implementation?

References

• Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest. 2012;42(9):1027–1036.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628.
   PubMed Web of Science ®Google Scholar
• Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol. 2015;30(5):713–725.
   PubMed Web of Science ®Google Scholar
• Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond). 2005;108(5):369–383.
   PubMed Web of Science ®Google Scholar
• Kolch W, Neususs C, Pelzing M, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005;24(6):959–977.
   PubMed Web of Science ®Google Scholar
• Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2009;8(1):268–281.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Suarez E, Siwy J, Zurbig P, et al. Urine as a source for clinical proteome analysis: from discovery to clinical application. BBA-Proteins Proteomics. 2014;1844(5):884–898.
   PubMed Web of Science ®Google Scholar
• Wood SL, Knowles MA, Thompson D, et al. Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol. 2013;10(4):206–218.
   PubMed Web of Science ®Google Scholar
• Belczacka I, Latosinska A, Metzger J, et al. Proteomics biomarkers for solid tumors: current status and future prospects. Mass Spectrom Rev. 2018.
   PubMedGoogle Scholar
• Frantzi M, Latosinska A, Merseburger AS, et al. Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. Expert Rev Mol Diagn. 2015;15(12):1539–1554.
   PubMed Web of Science ®Google Scholar
• Latosinska A, Frantzi M, Merseburger AS, et al. Promise and implementation of proteomic prostate cancer biomarkers. Diagnostics (Basel). 2018;8(3):1-27.
   PubMedGoogle Scholar
• Duijvesz D, Burnum-Johnson KE, Gritsenko MA, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One. 2013;8(12):e82589.
   PubMed Web of Science ®Google Scholar
• Principe S, Jones EE, Kim Y, et al. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013;13(10–11):1667–1671.
   PubMed Web of Science ®Google Scholar
• Overbye A, Skotland T, Koehler CJ, et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 2015;6(30):30357–30376.
   PubMed Web of Science ®Google Scholar
• Wang L, Skotland T, Berge V, et al. Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation. Eur J Pharm Sci. 2017;98:80–85.
   PubMed Web of Science ®Google Scholar
• Fujita K, Kume H, Matsuzaki K, et al. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep. 2017;7:9.
   PubMedGoogle Scholar
• Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y. Potential urinary protein biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5(2):103–114.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Kiprijanovska S, Komina S, et al. Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci. 2015;13:17.
   PubMed Web of Science ®Google Scholar
• Adeola HA, Soares NC, Paccez JD, et al. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry. Proteomics Clin Appl. 2015;9(5–6):597–609.
   PubMed Web of Science ®Google Scholar
• Kim Y, Jeon J, Mejia S, et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun. 2016;7:10.
   Web of Science ®Google Scholar
• Sequeiros T, Rigau M, Chiva C, et al. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget. 2017;8(3):4960–4976.
   PubMed Web of Science ®Google Scholar
• Shen H, Zhang L, Zhou JJ, et al. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) acts as a potential diagnostic biomarker for prostate cancer. Med Sci Monit. 2017;23:216–222.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Kiprijanovska S, Kostovska IM, et al. Comparative proteomics analysis of urine reveals down-regulation of acute phase response signaling and LXR/RXR activation pathways in prostate cancer. Proteomes. 2018;6(1):25.
   Web of Science ®Google Scholar
• Raimondo F, Morosi L, Corbetta S, et al. Differential protein profiling of renal cell carcinoma urinary exosomes. Mol Biosyst. 2013;9(6):1220–1233.
   PubMed Web of Science ®Google Scholar
• White NMA, Masui O, DeSouza LV, et al. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014;5(2):506–518.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Metzger J, Banks RE, et al. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J Proteomics. 2014;98:44–58.
   PubMed Web of Science ®Google Scholar
• Chinello C, Cazzaniga M, De Sio G, et al. Urinary signatures of renal cell carcinoma investigated by peptidomic approaches. PLoS One. 2014;9(9):10.
   Web of Science ®Google Scholar
• Mandili G, Notarpietro A, Khadjavi A, et al. Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients. Biomarkers. 2018;23(2):123–130.
   PubMed Web of Science ®Google Scholar
• Pontillo C, Jacobs L, Staessen JA, et al. A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol Dial Transplant. 2017;32(9):1510–1516.
   PubMed Web of Science ®Google Scholar
• Schanstra JP, Zurbig P, Alkhalaf A, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol. 2015;26(8):1999–2010.
   PubMed Web of Science ®Google Scholar
• Chen CL, Lin TS, Tsai CH, et al. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J Proteomics. 2013;85:28–43.
   PubMed Web of Science ®Google Scholar
• Filip S, Vougas K, Zoidakis J, et al. Comparison of depletion strategies for the enrichment of low-abundance proteins in urine. PLoS One. 2015;10(7):e0133773.
   PubMed Web of Science ®Google Scholar
• Lei T, Zhao XH, Jin S, et al. Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clin Genitourin Cancer. 2013;11(1):56–62.
   PubMed Web of Science ®Google Scholar
• Bryan RT, Regan HL, Pirrie SJ, et al. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. Br J Cancer. 2015;112(6):1052–1058.
   PubMed Web of Science ®Google Scholar
• Kumar P, Nandi S, Tan TZ, et al. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 2015;6(15):13539–13549.
   PubMedGoogle Scholar
• Frantzi M, van Kessel KE, Zwarthoff EC, et al. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin Cancer Res. 2016;22(16):4077–4086.
   PubMed Web of Science ®Google Scholar
• Egloff SAA, Du LP, Loomans HA, et al. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017;8(1):722–741.
   PubMedGoogle Scholar
• Azevedo R, Soares J, Gaiteiro C, et al. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. Talanta. 2018;184:347–355.
   PubMed Web of Science ®Google Scholar
• Vadasz Z, Rubinstein J, Bejar J, et al. Overexpression of semaphorin 3A in patients with urothelial cancer. Urol Oncol Semin Original Invest. 2018;36(4):6.
   Web of Science ®Google Scholar
• Lee J, McKinney KQ, Pavlopoulos AJ, et al. Altered proteome of extracellular vesicles derived from bladder cancer patients urine. Mol Cells. 2018;41(3):179–187.
   PubMed Web of Science ®Google Scholar
• Narayan VM, Adejoro O, Schwartz I, et al. The prevalence and impact of urinary marker testing in patients with bladder cancer. J Urol. 2018;199(1):74–80.
   PubMed Web of Science ®Google Scholar
• Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut. 2013;62(1):122–130.
   PubMed Web of Science ®Google Scholar
• Voigtlander T, Metzger J, Schonemeier B, et al. A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. United European Gastroenterol J. 2017;5(5):668–676.
   PubMed Web of Science ®Google Scholar
• Radon TP, Massat NJ, Jones R, et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clin Cancer Res. 2015;21(15):3512–3521.
   PubMed Web of Science ®Google Scholar
• Beretov J, Wasinger VC, Millar EKA, et al. Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach. PLoS One. 2015;10(11):20.
   Web of Science ®Google Scholar
• Gajbhiye A, Dabhi R, Taunk K, et al. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics. Proteomics. 2016;16(17):2403–2418.
   PubMed Web of Science ®Google Scholar
• Jia MM, Deng J, Cheng XL, et al. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget. 2017;8(6):9660–9671.
   PubMedGoogle Scholar
• Sandow JJ, Rainczuk A, Infusini G, et al. Discovery and validation of novel protein biomarkers in ovarian cancer patient urine. Proteomics Clin Appl. 2018;12(3):10.
   Web of Science ®Google Scholar
• Zhang C, Leng W, Sun C, et al. Urine proteome profiling predicts lung cancer from control cases and other tumors. EBioMedicine. 2018;30:120–128.
   PubMed Web of Science ®Google Scholar
• Belczacka I, Latosinska A, Siwy J, et al. Urinary CE-MS peptide marker pattern for detection of solid tumors. Sci Rep. 2018;8(1):5227.
   PubMedGoogle Scholar
• Stalmach A, Albalat A, Mullen W, et al. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis. 2013;34(11):1452–1464.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Latosinska A, Fluhe L, et al. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015;12(6):317–330.
   PubMed Web of Science ®Google Scholar
• Dhondt B, Van Deun J, Vermaerke S, et al. Urinary extracellular vesicle biomarkers in urological cancers: from discovery towards clinical implementation. Int J Biochem Cell Biol. 2018;99:236–256.
   PubMed Web of Science ®Google Scholar
• Bauca JM, Martinez-Morillo E, Diamandis EP. Peptidomics of urine and other biofluids for cancer diagnostics. Clin Chem. 2014;60(8):1052–1061.
   PubMed Web of Science ®Google Scholar
• Mischak H, Critselis E, Hanash S, et al. Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol. 2015;181(9):635–647.
   PubMed Web of Science ®Google Scholar
• Mischak H. Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrol Dial Transplant. 2015;30(4):532–537.
   PubMed Web of Science ®Google Scholar
• Vlahou A. Back to the future in bladder cancer research. Expert Rev Proteomics. 2011;8(3):295–297.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Latosinska A, Kontostathi G, et al. Clinical proteomics: closing the gap from discovery to implementation. Proteomics. 2018;18(14):8.
   Web of Science ®Google Scholar
• Dakna M, Harris K, Kalousis A, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010;11:594.
   PubMed Web of Science ®Google Scholar
• Mischak H, Vlahou A, Righetti PG, et al. Putting value in biomarker research and reporting. J Proteomics. 2014;96:A1–3.
   PubMed Web of Science ®Google Scholar
• Di Meo A, Bartlett J, Cheng YF, et al. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16:14.
   PubMed Web of Science ®Google Scholar
• Latosinska A, Frantzi M, Vlahou A, et al. Clinical proteomics for precision medicine: the bladder cancer case. Proteomics Clin Appl. 2018;12(2):1700074.
   PubMed Web of Science ®Google Scholar
• Nawaz M, Camussi G, Valadi H, et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol. 2014;11(12):688–701.
   PubMed Web of Science ®Google Scholar
• Mischak H, Kolch W, Aivaliotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl. 2010;4(4):464–478.
   PubMed Web of Science ®Google Scholar
• Pejchinovski M, Hrnjez D, Ramirez-Torres A, et al. Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics. Proteomics Clin Appl 2015;9(5–6):453–468.
   PubMed Web of Science ®Google Scholar
• Magalhaes P, Pontillo C, Pejchinovski M, et al. Comparison of urine and plasma peptidome indicates selectivity in renal peptide handling. Proteomics Clin Appl. 2018;12(5):e1700163.
   PubMed Web of Science ®Google Scholar